Cue Biopharma, Inc. · NASDAQ:CUE
Cue Biopharma — Investor Presentation (January 2020)
20 slides from Cue Biopharma's investor presentation, January 2020
Slide 1: Corporate Presentation
Corporate Presentation Immune Responses, On Cue™ Nasdaq: CUE | January 2020
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation has been prepared by Cue Biopharma, Inc. (“we,” “us,” “our,” “Cue” or the “Company”) and is made for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities, nor shall there be any sale of any s
Slide 3: Corporate Highlights
Corporate Highlights Disruptive Platform for Focused Execution Against Strategic Partnerships to T Cell Modulation In Vivo Platform Validation Accelerate Expansion • Distinct mechanism of action for the • CUE-101 in Phase 1 for recurrent/ • LG Chem collaboration to expand selective and specific modu
Slide 4: Emulating Nature's Cues to Selectively Modulate T Cells
Emulating Nature’s Cues to Selectively Modulate T Cells Co-Stimulatory/ T Cell Immuno-STAT Co-Regulatory T Cell Receptor Receptor (TCR) Signal 1 Signal 2 Signal 2 Signal 1 Induction/ Selectivity/ Control Specificity FC Co-Stimulatory/ Major Co-Regulatory Histocompatibility Fc Signal Complex (MHC) An
Slide 5: Immuno-STAT Modularity
Immuno-STAT Modularity MHC Peptide Different HLA alleles to Peptide epitopes to target address global patient different diseases populations Co-stim/Co-reg Fc Backbone Distinct biological signals, Fc engineering to dial in or dial including cytokines; cell-surface out biological and effector recepto
Slide 6: Immuno-STATs Selectively Modulate Disease Relevant T Cells
Immuno-STATs Selectively Modulate Disease Relevant T Cells Oncology Autoimmune Disease MART1 and IL-2 in Human PBMCs IGRP and PD-L1 in NOD Mice Pat hog 4 eni cA cific T C utore % Antigen Specific T cells p e ells act % Antigen Specific T cells 3 um or S lls ive T e TC 2 1 0 Media Low High Media Low
Slide 7: Pipeline
Pipeline TARGET SELECTION PRE-CLINICAL PHASE 1 LATE CLINICAL PARTNER CUE-101 (HPV E7 / A02) CUE-100 CUE-102 (WT1 / A02) IL-2 Asia Rights to Three Oncology CUE-102 (WT1 / A24) Targets CUE-200 CUE-103 (Undisclosed) CD80 & 4-1BBL CUE-201 (Undisclosed) CUE-301 (Undisclosed) CUE-300 Collaboration for Aut
Slide 8: CUE-100 Series: Exploiting IL-2 via Rational Protein Design
CUE-100 Series: Exploiting IL-2 via Rational Protein Design Immune Signaling Components CUE-100 Series Optimized for desired biological activity through two single amino acid changes • Abrogates binding to IL-2R alpha Attenuated IL-2 • Reduces binding affinity to IL-2R beta Side View Maintains IL-2
Slide 9: CUE-100 Series: Mechanistic Differentiation Over Emerging "Not Alpha" IL-2 Landscape
CUE-100 Series: Mechanistic Differentiation Over Emerging “Not Alpha” IL-2 Landscape Wild Type IL-2 “Not Alpha” IL-2 CUE-100 IL-2 Series (e.g., Proleukin) (e.g., THOR-707) (e.g., CUE-101) IL-2R⍺ ✔ ✔ +/- X ✔ +/- X X ✔ IL-2Rβ Non-tumor Anti-tumor Non-tumor Anti-tumor Non-tumor Anti-tumor Treg Treg Tre
Slide 10: CUE-101: Lead Clinical Candidate for HPV-Driven Malignancies
CUE-101: Lead Clinical Candidate for HPV-Driven Malignancies CUE-101 Immuno-STAT Design Clinical Rationale • HPV+ head and neck cancer is a significant issue in Signal 1: western markets, with reported 2.5% annual growth in HLA-A*02:01 + HPV-16 E711-20 peptide incidence • Despite treatment with curr
Slide 11: CUE-101: Ongoing First-In-Human Study
CUE-101: Ongoing First-In-Human Study • Design (CUE-101 Q3W) Part A: Monotherapy Dose Escalation - Part A: Dose Escalation (3+3) - Part A: Safety Expansion (Up to 9 Patients) Cohort N - Part B: Dose Expansion (10-20 Pts at RP2D) Cohort 3 • Eligibility RP2D:BED/MTD - Part A & B: HPV+ H&N Cancer, R/M
Slide 12: CUE-101: Directing IL-2 to the "Right" T Cells
CUE-101: Directing IL-2 to the “Right” T Cells Selective Binding Intact & Selective Effector Function 90 HPV-specific CD8+ T cells CMV-specific CD8+ T cells % CUE-101 Bound Cells HPV E711-20 CD8+ T Cells 80 CMV pp65495-503 CD8+ T Cells 70 Naive CD8+ T Cells 60 50 40 30 20 10 0 0.001 0.01 0.1 1 10 10
Slide 13: CUE-101: In Vitro Expansion of E7-Specific T Cells
CUE-101: In Vitro Expansion of E7-Specific T Cells Vehicle-Treated CUE-101-Treated 107 Immune Cell Subsets (absolute counts) 106 105 104 103 102 E711-20-Specific CD8+ T Cells 101 100 0.01 0.1 1 10 100 1000 10000 [CUE-101] (nM) E711-20-specific CD8+ T cells CD4+ T cells CD8+ T cells CD4+ CD25+ Foxp3+
Slide 14: CUE-101 vs Wild-Type IL-2: Mitigating the Risk Associated with Systemic IL-2 Activation
CUE-101 vs Wild-Type IL-2: Mitigating the Risk Associated with Systemic IL-2 Activation • PBMC from healthy human donors were stimulated for 18 hours with increasing amounts of CUE-101 or recombinant human IL-2 • Cytokine production was assessed in culture supernatant by MSD 14 © 2020 CUE BIOPHARMA
Slide 15: CUE-101 Surrogate: Activity in an In Vivo Preclinical Model
CUE-101 Surrogate: Activity in an In Vivo Preclinical Model TC1 Tumor Model: Specific T Cell Expansion Antigen-Specific TILs are Improved Survival (mono vs in Tumors Cytolytic combo w/ anti-PD-1) ** 100 60 50 % of CD107a+, Granzyme B+ % AgS among CD8+ T cells * % IFNγ+ of CD8+ T cells *** 40 *** of
Slide 16: CUE-101 Surrogate: Activity in an In Vivo Preclinical Model
CUE-101 Surrogate: Activity in an In Vivo Preclinical Model Induction of Memory Dependent Long Term Memory Upon CD8+ T cells 1500 Tumor volume (mm3) 100 1200 Overall Survival (%) 75 900 600 50 Treatment Naive Naive Isotype *** 300 Combo Prior Treated Treatment 25 CD4 depleted CD8 depleted 0 Tumor na
Slide 17: Building Blocks of IO Growth Strategy
Building Blocks of IO Growth Strategy • Increase R&D efficiency via chemical attachment of antigens to HLA Scalability • Enable access to post-translationally modified and personalized peptides (i.e., neoantigens) as both a single target or mixture Neo- STATTM Antigen & • Address broader set of tumo
Slide 18: CUE-100 Series Extensibility: CUE-102 and KRAS
CUE-100 Series Extensibility: CUE-102 and KRAS CUE-101 CUE-102 KRAS A02 HPV WT-1 KRAS G12V Allele Expansion A24 WT-1 A11 KRAS G12V Clinical Preclinical Target Selection 18 © 2020 CUE BIOPHARMA
Slide 19: Neo-STAT: Next-gen Evolution of the Immuno-STAT Framework
Neo-STAT: Next-gen Evolution of the Immuno-STAT Framework CUE-100 Neo-STAT Top Therapeutic scaffold receptive for View Therapeutic scaffold chemical conjugation of peptides, that manufactured in bulk potentially: • Increases R&D efficiency and reduces cost of the generation of clinical grade materia
Slide 20: Corporate Highlights
Corporate Highlights Disruptive Platform for Focused Execution Against Strategic Partnerships to T Cell Modulation In Vivo Platform Validation Accelerate Expansion • Distinct mechanism of action for the • CUE-101 in Phase 1 for recurrent/ • LG Chem collaboration to expand selective and specific modu